Coenzyme Q10 Slow-Release Drug Multilayer Structure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing clinical coenzyme Q10 drugs have limited effectiveness in providing long-term cardiac protection and are burdened by the risk of myocardial infarction.
Innovation Solution
A coenzyme Q10 slow-release drug with a multilayer structure, comprising a degradable gel isolation layer and a drug layer containing coenzyme Q10 and a pharmaceutically acceptable carrier, is developed to achieve controlled release and enhanced therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If traditional coenzyme Q10 drugs are used, then the drug can be administered, but the therapeutic effect is limited and cannot provide long-term cardiac protection
Solution Approach 1:
The drug is divided into multiple layers with different functions: a drug layer containing coenzyme Q10, a degradable gel isolation layer for controlled release, and an outer isolation layer. This segmentation allows the drug to release coenzyme Q10 gradually over time, providing long-term cardiac protection while maintaining effective therapeutic levels.
Solution Approach 2:
The multilayer structure is pre-designed with specific materials and thicknesses to control the release rate of coenzyme Q10 before administration. The degradable gel isolation layer is prepared in advance with controlled degradation properties, ensuring that the drug releases at an optimal rate once implanted, thereby extending the duration of action without compromising therapeutic effectiveness.
2Reliability
If the drug release rate is increased, then the therapeutic effect is enhanced, but the duration of action is reduced
Solution Approach 1:
The degradable gel isolation layer provides dynamic control over drug release. As the gel degrades over time, the release rate of coenzyme Q10 changes dynamically, initially providing high concentration for immediate therapeutic effect, then gradually reducing to maintain effective levels over an extended period. This dynamic release profile resolves the contradiction between rapid therapeutic effect and prolonged duration.
3Reliability
If a multilayer structure is used, then the controlled release is achieved, but the device complexity increases
Solution Approach 1:
The multilayer structure utilizes thin film layers: a drug layer, a degradable gel isolation layer, and an outer isolation layer. These thin film structures achieve controlled release functionality without requiring complex mechanical components or sophisticated engineering, thereby limiting the increase in device complexity while maintaining reliable controlled release performance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The coenzyme Q10 slow-release drug effectively reduces myocardial infarction size, provides excellent protective and repair effects on myocardial ischemic injury, and offers a more efficient therapeutic outcome compared to traditional slow-release drugs.
Implementation Method 1
the isolation layer is composed of a degradable gel
Implementation Method 2
CoQ10 has the functions of improving human immunity, offering an antioxidant effect, delaying aging and enhancing the human vitality
Data Source
AI summary
A coenzyme Q10 slow-release drug includes an isolation layer and a drug layer, where the drug layer is composed of coenzyme Q10 and a pharmaceutically acceptable carrier; the isolation layer is composed of a degradable gel; a diameter of the drug layer is not larger than that of the isolation layer. The coenzyme Q10 slow-release drug is prepared as follows. (S1) The degradable gel is laid on a mold for casting into a film to form the isolation layer. (S2) Coenzyme Q10 and the pharmaceutically acceptable carrier are mixed and laid on the mold in step (S1) for casting to form the drug layer on the isolation layer. (S3) Steps (S1) and (S2) are repeated, and then edges of adjacent controlled-release layers are bonded to obtain the coenzyme Q10 slow-release drug.